Gemcitabine, Busulfan and Melphalan (Gem/Bu/Mel) Is a New High-Dose Chemotherapy (HDC) Regimen with High Activity in Refractory or Poor-Risk Relapsed Non-Hodgkin'S Lymphoma (NHL) Patients Receiving an Autologous Stem-Cell Transplant (ASCT)

✍ Scribed by Y. Nieto; R.B. Jones; U. Popat; B. Andersson; B. Valdez; P. Thall; E.J. Shpall; C. Chancoco; A. Alousi; P. Anderlini; C. Hosing; M. Qazilbash; Q. Bashir; P. Kebriaei; I. Khoui; S. Ciurea; S. Parmar; G. Rondon; R. Champlin

• Book ID: 116282851
• Publisher: Elsevier Science
• Year: 2012
• Tongue: English
• Weight: 56 KB
• Volume: 18
• Category: Article
• ISSN: 1083-8791
• DOI: 10.1016/j.bbmt.2011.12.012